The Inflation Reduction Act and Its Implications on Real-World Evidence
The Inflation Reduction Act (IRA), passed in August 2022, targets reducing prescription drug prices for Medicare beneficiaries in the US. It introduces three major reforms:
-
Medicare Part D Changes: This affects how prescription drugs are covered under Medicare Part D.
-
Inflationary Caps in Medicare Part B: Sets limits on price increases for Medicare Part B services.
-
Medicare Price Negotiation: Allows Medicare to negotiate drug prices directly, impacting how pharmaceutical companies present evidence.
Contact us at connect@axtria.com with any questions.
Complete the brief form to download the white paper
Stay current on topics you care about
Recommended insights

Case Study
Long-Term Partnership Helps Advance Real World Evidence in Regulatory and Clinical Decision-Making

White Paper
Digital Twins: A Fit-for-Purpose Solution to Elevate Clinical Trial Power and Efficiency